ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

AstraZeneca, Amgen and Qilu Pharmaceutical side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

AstraZeneca×Amgen×Qilu Pharmaceutical×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AstraZenecaAmgenQilu Pharmaceutical
studies on the registry4,1971,088219
open to participants now29850136
phase 3 studies under way2005053
reach primary completion within a year1683550
programswith a study of their own in two years119+5 named only2472

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAstraZenecaAmgenQilu Pharmaceutical
Phase 1

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

Amgen: 8 of its 24 programs at phase 1

  1. AMG 691phase 1
  2. AMG 127phase 1
  3. etakafusp alfaphase 1
  4. Pan-KRAS Inhibitor AMG 410phase 1
  5. tambotatug pelitecanphase 1

and 3 more — sign in to see them all

33%

Qilu Pharmaceutical: 24 of its 72 programs at phase 1

  1. apripitant and palonosetron injectable emulsionphase 1
  2. follitropin alfaphase 1
  3. Meropenem-Pralubactamphase 1
  4. QL2302phase 1
  5. QLF4113phase 1

and 19 more — sign in to see them all

33%
Phase 2

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%

Amgen: 1 of its 24 programs at phase 2

  1. AMG 732phase 2
4%

Qilu Pharmaceutical: 14 of its 72 programs at phase 2

  1. QLS1410phase 2
  2. QLS12010phase 2
  3. KRAS G12D Inhibitor QLC1101phase 2
  4. QLH12016phase 2
  5. QLC1401phase 2

and 9 more — sign in to see them all

19%
Phase 3

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%

Amgen: 7 of its 24 programs at phase 3

  1. maridebart cafraglutidephase 3
  2. tarlatamabphase 3
  3. xaluritamigphase 3
  4. sotorasibphase 3
  5. olpasiranphase 3

and 2 more — sign in to see them all

29%

Qilu Pharmaceutical: 32 of its 72 programs at phase 3

  1. Iparomlimab/Tuvonralimabphase 3
  2. QLC5508phase 3
  3. Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905phase 3
  4. QL2107phase 3
  5. QLC7401phase 3

and 27 more — sign in to see them all

44%
Approved, new studies

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

Amgen: 8 of its 24 programs at approved, new studies

  1. inebilizumabapproved, new study
  2. blinatumomabapproved, new study
  3. apremilastapproved, new study
  4. evolocumabapproved, new study
  5. romiplostimapproved, new study

and 3 more — sign in to see them all

33%

Qilu Pharmaceutical: 2 of its 72 programs at approved, new studies

  1. Dimethyl Fumarate Enteric-coated Capsulesapproved, new study
  2. Tafamidis Meglumine Soft Capsulesapproved, new study
3%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
AstraZeneca60 readouts · 16 phase 3

AstraZeneca, Nov ’26: 4 programs whose next study reaches primary completion

  1. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  2. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  3. durvalumabapproved, new study · Nov 30 · NCT07081633
  4. tremelimumabphase 3 · Nov 30 · NCT07081633

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 13 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 8 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
Amgen12 readouts · 3 phase 3·

Amgen, Dec ’26: 1 program whose next study reaches primary completion

  1. sotorasibphase 3 · Dec 17 · NCT04185883

Amgen, Jan ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. AMG 732phase 2 · Jan 6 · NCT06401044
  2. apremilastapproved, new study · Jan 10 · NCT07908641
  3. romosozumabapproved, new study · Jan 14 · NCT07811999
  4. maridebart cafraglutidephase 3 · Jan 21 · NCT06858839

Amgen, Feb ’27: 1 program whose next study reaches primary completion

  1. xaluritamigphase 3 · Feb 17 · NCT06613100

Amgen, Mar ’27: 1 program whose next study reaches primary completion

  1. AMG 691phase 1 · Mar 17 · NCT07745907

Amgen, Apr ’27: 2 programs whose next study reaches primary completion

  1. inebilizumabapproved, new study · Apr 13 · NCT05549258
  2. tarlatamabphase 3 · Apr 24 · NCT06598306

Amgen, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. evolocumabapproved, new study · May 29 · NCT05284747
·

Amgen, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. afliberceptphase 3 · Jul 31 · NCT07614776
··

Amgen, Oct ’27: 1 program whose next study reaches primary completion

  1. AMG 127phase 1 · Oct 2 · NCT07590193
Qilu Pharmaceutical37 readouts · 13 phase 3

Qilu Pharmaceutical, Nov ’26: 2 programs whose next study reaches primary completion

  1. apripitant and palonosetron injectable emulsionphase 1 · Nov 0 · NCT07817004
  2. QLS1304phase 2 · Nov 0 · NCT06823609

Qilu Pharmaceutical, Dec ’26: 9 programs whose next study reaches primary completion, 4 in phase 3

  1. Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905phase 3 · Dec 0 · NCT06942767
  2. pralurbactamphase 3 · Dec 0 · NCT07089186
  3. QL1207Hphase 3 · Dec 0 · NCT07489586
  4. QL2107phase 3 · Dec 0 · NCT06754644
  5. QLG1091phase 3 · Dec 0 · NCT07487103

and 4 more — sign in to see them all

Qilu Pharmaceutical, Jan ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. QL1206phase 3 · Jan 0 · NCT07062978
  2. QLS1510phase 1 · Jan 30 · NCT07760077

Qilu Pharmaceutical, Feb ’27: 1 program whose next study reaches primary completion

  1. QLC1401phase 2 · Feb 0 · NCT07173556

Qilu Pharmaceutical, Mar ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. QLH2405phase 1 · Mar 0 · NCT07489599
  2. QLM3003phase 3 · Mar 0 · NCT06880276

Qilu Pharmaceutical, Apr ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. Anti-HER2 Monoclonal Antibody QL1209phase 3 · Apr 0 · NCT07861139
  2. Platinum Compoundsphase 2 · Apr 0 · NCT07453394
  3. QLS1209phase 1 · Apr 0 · NCT06872580
  4. QLS5132phase 3 · Apr 0 · NCT07453394
  5. QL0911phase 3 · Apr 30 · NCT06456528

Qilu Pharmaceutical, May ’27: 4 programs whose next study reaches primary completion, 4 in phase 3

  1. Anti-B7-H3 Antibody-drug Conjugate MHB088Cphase 3 · May 0 · NCT06954246
  2. daprodustatphase 3 · May 0 · NCT07300111
  3. QL2108phase 3 · May 0 · NCT06884891
  4. QLG2128phase 3 · May 0 · NCT06898060

Qilu Pharmaceutical, Jun ’27: 7 programs whose next study reaches primary completion, 1 in phase 3

  1. Anti-TROP2 Antibody-drug Conjugate ESG401phase 3 · Jun 0 · NCT06732323
  2. Iparomlimab/Tuvonralimabphase 3 · Jun 0 · NCT07272590
  3. QL2401phase 2 · Jun 0 · NCT07620366
  4. QLC5513phase 2 · Jun 0 · NCT07272590
  5. QLS5308phase 1 · Jun 0 · NCT07462442

and 2 more — sign in to see them all

Qilu Pharmaceutical, Jul ’27: 1 program whose next study reaches primary completion

  1. QLS5133phase 2 · Jul 0 · NCT07061639

Qilu Pharmaceutical, Aug ’27: 1 program whose next study reaches primary completion

  1. QLS2406-1 injectionphase 1 · Aug 30 · NCT07937787
·

Qilu Pharmaceutical, Oct ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. QLC7401phase 3 · Oct 7 · NCT07444086
  2. QLS2312phase 1 · Oct 9 · NCT07861581
  3. QLS7402 Injectionphase 1 · Oct 29 · NCT07950462
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Amgen

New programs 0

None

Reached a new phase 0

None

Study stopped 1

Primary completion later 5

Qilu Pharmaceutical

New programs 7

Reached a new phase 2

  • QLS4131phase 3 · Nov 6 · Multiple Myeloma
  • QLS5132phase 3 · Oct 20 · Carcinoma, Ovarian Epithelial

Study stopped 0

None

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 59 in all. A program counts in each condition its studies name most.

ConditionAstraZenecaAmgenQilu Pharmaceutical
Carcinoma, Non-Small-Cell Lungall three · compare here

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 16 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 11 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Amgen in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. sotorasibphase 3
  2. Pan-KRAS Inhibitor AMG 410phase 1
  3. tambotatug pelitecanphase 1
  4. romiplostimapproved, new study

Their studies: Amgen’s studies of Carcinoma, Non-Small-Cell Lung in search

Qilu Pharmaceutical in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. Iparomlimab/Tuvonralimabphase 3
  2. QL2107phase 3
  3. romiplostimphase 3
  4. Platinum Compoundsphase 2

Their studies: Qilu Pharmaceutical’s studies of Carcinoma, Non-Small-Cell Lung in search

Prostatic Neoplasmsall three · compare here

AstraZeneca in Prostatic Neoplasms: 13 programs

  1. saruparibphase 3
  2. capivasertibphase 3
  3. zibotentanphase 3
  4. Actinium-225phase 3
  5. zadavotide guraxetanphase 2

and 8 more — sign in to see them all

Their studies: AstraZeneca’s studies of Prostatic Neoplasms in search

Amgen in Prostatic Neoplasms: 2 programs

  1. tarlatamabphase 3
  2. xaluritamigphase 3

Their studies: Amgen’s studies of Prostatic Neoplasms in search

Qilu Pharmaceutical in Prostatic Neoplasms: 5 programs

  1. QLC5508phase 3
  2. QLG1080phase 3
  3. QLH12016phase 2
  4. QLF4113phase 1
  5. QLS2401phase 1

Their studies: Qilu Pharmaceutical’s studies of Prostatic Neoplasms in search

Asthmaall three · compare here

AstraZeneca in Asthma: 10 programs

  1. tozorakimabphase 3
  2. BFF MDIphase 3
  3. GP MDIphase 3
  4. londamocitinibphase 2
  5. sunakimentphase 2

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Asthma in search

Amgen in Asthma: 1 program

  1. AMG 691phase 1

Their studies: Amgen’s studies of Asthma in search

Qilu Pharmaceutical in Asthma: 1 program

  1. tezepelumabphase 3

Their studies: Qilu Pharmaceutical’s studies of Asthma in search

Neoplasmsall three · compare here

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Amgen in Neoplasms: 2 programs

  1. tarlatamabphase 3
  2. teprotumumabapproved, new study

Their studies: Amgen’s studies of Neoplasms in search

Qilu Pharmaceutical in Neoplasms: 2 programs

  1. QL2107phase 3
  2. QL2109phase 3

Their studies: Qilu Pharmaceutical’s studies of Neoplasms in search

Small Cell Lung Carcinomaall three · compare here

AstraZeneca in Small Cell Lung Carcinoma: 2 programs

  1. tremelimumabphase 3
  2. durvalumabapproved, new study

Their studies: AstraZeneca’s studies of Small Cell Lung Carcinoma in search

Amgen in Small Cell Lung Carcinoma: 4 programs

  1. tarlatamabphase 3
  2. etakafusp alfaphase 1
  3. tambotatug pelitecanphase 1
  4. Zocilurtatug Pelitecanphase 1

Their studies: Amgen’s studies of Small Cell Lung Carcinoma in search

Diabetes Mellitus, Type 2all three · compare here

AstraZeneca in Diabetes Mellitus, Type 2: 5 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD6793phase 2
  4. Elecoglipron Test formulation 1 Dose Aphase 1
  5. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus, Type 2 in search

Amgen in Diabetes Mellitus, Type 2: 2 programs

  1. maridebart cafraglutidephase 3
  2. AMG 127phase 1

Their studies: Amgen’s studies of Diabetes Mellitus, Type 2 in search

Qilu Pharmaceutical in Diabetes Mellitus, Type 2: 1 program

  1. QLG1091phase 3

Their studies: Qilu Pharmaceutical’s studies of Diabetes Mellitus, Type 2 in search

Lupus Erythematosus, Systemicall three · compare here

Amgen in Lupus Erythematosus, Systemic: 1 program

  1. inebilizumabapproved, new study

Their studies: Amgen’s studies of Lupus Erythematosus, Systemic in search

Qilu Pharmaceutical in Lupus Erythematosus, Systemic: 3 programs

  1. QLS4131phase 3
  2. QLS2404phase 1
  3. QLS2416phase 1

Their studies: Qilu Pharmaceutical’s studies of Lupus Erythematosus, Systemic in search

Obesityall three · compare here

AstraZeneca in Obesity: 4 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD9550phase 2
  4. AZD1043phase 1

Their studies: AstraZeneca’s studies of Obesity in search

Amgen in Obesity: 1 program

  1. maridebart cafraglutidephase 3

Their studies: Amgen’s studies of Obesity in search

Qilu Pharmaceutical in Obesity: 2 programs

  1. QLS2406-1 injectionphase 1
  2. QLS7402 Injectionphase 1

Their studies: Qilu Pharmaceutical’s studies of Obesity in search

Colorectal Neoplasmsall three · compare here

AstraZeneca in Colorectal Neoplasms: 1 program

  1. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Colorectal Neoplasms in search

Amgen in Colorectal Neoplasms: 2 programs

  1. sotorasibphase 3
  2. afliberceptphase 3

Their studies: Amgen’s studies of Colorectal Neoplasms in search

Qilu Pharmaceutical in Colorectal Neoplasms: 2 programs

  1. Iparomlimab/Tuvonralimabphase 3
  2. QL1203phase 3

Their studies: Qilu Pharmaceutical’s studies of Colorectal Neoplasms in search

Hypercholesterolemiaall three · compare here

AstraZeneca in Hypercholesterolemia: 2 programs

  1. laroprovstatphase 3
  2. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Hypercholesterolemia in search

Amgen in Hypercholesterolemia: 1 program

  1. evolocumabapproved, new study

Their studies: Amgen’s studies of Hypercholesterolemia in search

Qilu Pharmaceutical in Hypercholesterolemia: 2 programs

  1. QLC7401phase 3
  2. RBD7022phase 1

Their studies: Qilu Pharmaceutical’s studies of Hypercholesterolemia in search

Hyperlipidemiasall three · compare here

AstraZeneca in Hyperlipidemias: 3 programs

  1. laroprovstatphase 3
  2. Laroprovstat/ezetimibe FCDP-slow variantphase 1
  3. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Hyperlipidemias in search

Amgen in Hyperlipidemias: 1 program

  1. evolocumabapproved, new study

Their studies: Amgen’s studies of Hyperlipidemias in search

Qilu Pharmaceutical in Hyperlipidemias: 1 program

  1. RBD7022phase 1

Their studies: Qilu Pharmaceutical’s studies of Hyperlipidemias in search

Neoplasm Metastasisall three · compare here

AstraZeneca in Neoplasm Metastasis: 3 programs

  1. saruparibphase 3
  2. camizestrantphase 3
  3. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Neoplasm Metastasis in search

Amgen in Neoplasm Metastasis: 1 program

  1. WRN Inhibitor AMG 436phase 1

Their studies: Amgen’s studies of Neoplasm Metastasis in search

Qilu Pharmaceutical in Neoplasm Metastasis: 1 program

  1. QL1206phase 3

Their studies: Qilu Pharmaceutical’s studies of Neoplasm Metastasis in search

Arthritis, Rheumatoidall three · compare here

AstraZeneca in Arthritis, Rheumatoid: 2 programs

  1. surovatamigphase 3
  2. AZD1163phase 2

Their studies: AstraZeneca’s studies of Arthritis, Rheumatoid in search

Amgen in Arthritis, Rheumatoid: 1 program

  1. dazodalibepphase 3

Their studies: Amgen’s studies of Arthritis, Rheumatoid in search

Qilu Pharmaceutical in Arthritis, Rheumatoid: 1 program

  1. QLS12010phase 2

Their studies: Qilu Pharmaceutical’s studies of Arthritis, Rheumatoid in search

Pancreatic Neoplasmsall three · compare here

AstraZeneca in Pancreatic Neoplasms: 2 programs

  1. sonesitatug vedotinphase 3
  2. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Pancreatic Neoplasms in search

Amgen in Pancreatic Neoplasms: 1 program

  1. tambotatug pelitecanphase 1

Their studies: Amgen’s studies of Pancreatic Neoplasms in search

Purpura, Thrombocytopenic, Idiopathicall three · compare here

AstraZeneca in Purpura, Thrombocytopenic, Idiopathic: 1 program

  1. pirtobrutinibphase 2

Their studies: AstraZeneca’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Amgen in Purpura, Thrombocytopenic, Idiopathic: 1 program

  1. romiplostimapproved, new study

Their studies: Amgen’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Qilu Pharmaceutical in Purpura, Thrombocytopenic, Idiopathic: 2 programs

  1. QL0911phase 3
  2. romiplostimphase 3

Their studies: Qilu Pharmaceutical’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Lymphoma, Large B-Cell, Diffuseall three · compare here

AstraZeneca in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Lymphoma, Large B-Cell, Diffuse in search

Amgen in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. blinatumomabapproved, new study

Their studies: Amgen’s studies of Lymphoma, Large B-Cell, Diffuse in search

Qilu Pharmaceutical in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. selinexorphase 3

Their studies: Qilu Pharmaceutical’s studies of Lymphoma, Large B-Cell, Diffuse in search

Breast Neoplasms2 of 3 · compare here

AstraZeneca in Breast Neoplasms: 10 programs

  1. datopotamab deruxtecanphase 3
  2. saruparibphase 3
  3. capivasertibphase 3
  4. camizestrantphase 3
  5. puxitatug samrotecanphase 3

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Breast Neoplasms in search

–
Pulmonary Disease, Chronic Obstructive2 of 3 · compare here

AstraZeneca in Pulmonary Disease, Chronic Obstructive: 8 programs

  1. tozorakimabphase 3
  2. GP MDIphase 3
  3. AZD6793phase 2
  4. Treatment A: BGF MDI HFOphase 1
  5. tezepelumabapproved, new study

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Pulmonary Disease, Chronic Obstructive in search

–

Qilu Pharmaceutical in Pulmonary Disease, Chronic Obstructive: 1 program

  1. tezepelumabphase 3

Their studies: Qilu Pharmaceutical’s studies of Pulmonary Disease, Chronic Obstructive in search

Renal Insufficiency2 of 3 · compare here

AstraZeneca in Renal Insufficiency: 8 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. opemalirsenphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency in search

Amgen in Renal Insufficiency: 1 program

  1. olpasiranphase 3

Their studies: Amgen’s studies of Renal Insufficiency in search

–
Renal Insufficiency, Chronic2 of 3 · compare here

AstraZeneca in Renal Insufficiency, Chronic: 8 programs

  1. elecoglipronphase 3
  2. baxdrostatphase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. Berzanoflastphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency, Chronic in search

Amgen in Renal Insufficiency, Chronic: 1 program

  1. Pegloticaseapproved, new study

Their studies: Amgen’s studies of Renal Insufficiency, Chronic in search

–
Multiple Myeloma2 of 3 · compare here–

Qilu Pharmaceutical in Multiple Myeloma: 4 programs

  1. QL2109phase 3
  2. QLS4131phase 3
  3. QLS32015phase 3
  4. selinexorphase 3

Their studies: Qilu Pharmaceutical’s studies of Multiple Myeloma in search

Atherosclerosis2 of 3 · compare here

AstraZeneca in Atherosclerosis: 3 programs

  1. laroprovstatphase 3
  2. baxdrostatphase 3
  3. Berzanoflastphase 2

Their studies: AstraZeneca’s studies of Atherosclerosis in search

Amgen in Atherosclerosis: 2 programs

  1. maridebart cafraglutidephase 3
  2. olpasiranphase 3

Their studies: Amgen’s studies of Atherosclerosis in search

–
Dermatitis, Atopic2 of 3 · compare here

AstraZeneca in Dermatitis, Atopic: 1 program

  1. tezepelumabapproved, new study

Their studies: AstraZeneca’s studies of Dermatitis, Atopic in search

–

Qilu Pharmaceutical in Dermatitis, Atopic: 4 programs

  1. QLM3003phase 3
  2. QL2108phase 3
  3. tezepelumabphase 3
  4. QLS12010phase 2

Their studies: Qilu Pharmaceutical’s studies of Dermatitis, Atopic in search

Endometrial Neoplasms2 of 3 · compare here

AstraZeneca in Endometrial Neoplasms: 4 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. puxitatug samrotecanphase 3
  4. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Endometrial Neoplasms in search

–

Qilu Pharmaceutical in Endometrial Neoplasms: 1 program

  1. selinexorphase 3

Their studies: Qilu Pharmaceutical’s studies of Endometrial Neoplasms in search

Triple Negative Breast Neoplasms2 of 3 · compare here

AstraZeneca in Triple Negative Breast Neoplasms: 4 programs

  1. datopotamab deruxtecanphase 3
  2. capivasertibphase 3
  3. ceralasertibphase 3
  4. Actinium-225phase 3

Their studies: AstraZeneca’s studies of Triple Negative Breast Neoplasms in search

–

Qilu Pharmaceutical in Triple Negative Breast Neoplasms: 1 program

  1. Anti-TROP2 Antibody-drug Conjugate ESG401phase 3

Their studies: Qilu Pharmaceutical’s studies of Triple Negative Breast Neoplasms in search

Carcinoma, Renal Cell2 of 3 · compare here

AstraZeneca in Carcinoma, Renal Cell: 3 programs

  1. volrustomigphase 3
  2. Actinium-225phase 3
  3. casdatifanphase 1

Their studies: AstraZeneca’s studies of Carcinoma, Renal Cell in search

–

Qilu Pharmaceutical in Carcinoma, Renal Cell: 1 program

  1. QLS5133phase 2

Their studies: Qilu Pharmaceutical’s studies of Carcinoma, Renal Cell in search

Dyslipidemias2 of 3 · compare here

AstraZeneca in Dyslipidemias: 3 programs

  1. laroprovstatphase 3
  2. AZD4954phase 1
  3. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Dyslipidemias in search

Amgen in Dyslipidemias: 1 program

  1. evolocumabapproved, new study

Their studies: Amgen’s studies of Dyslipidemias in search

–
Lymphoma, B-Cell2 of 3 · compare here

Amgen in Lymphoma, B-Cell: 1 program

  1. blinatumomabapproved, new study

Their studies: Amgen’s studies of Lymphoma, B-Cell in search

–
Cardiovascular Diseases2 of 3 · compare here

AstraZeneca in Cardiovascular Diseases: 2 programs

  1. laroprovstatphase 3
  2. balcinrenonephase 3

Their studies: AstraZeneca’s studies of Cardiovascular Diseases in search

Amgen in Cardiovascular Diseases: 1 program

  1. olpasiranphase 3

Their studies: Amgen’s studies of Cardiovascular Diseases in search

–
Colonic Neoplasms2 of 3 · compare here

AstraZeneca in Colonic Neoplasms: 2 programs

  1. oleclumabphase 3
  2. monalizumabphase 3

Their studies: AstraZeneca’s studies of Colonic Neoplasms in search

–

Qilu Pharmaceutical in Colonic Neoplasms: 1 program

  1. Iparomlimab/Tuvonralimabphase 3

Their studies: Qilu Pharmaceutical’s studies of Colonic Neoplasms in search

Hematologic Neoplasms2 of 3 · compare here

AstraZeneca in Hematologic Neoplasms: 1 program

  1. capivasertibphase 3

Their studies: AstraZeneca’s studies of Hematologic Neoplasms in search

–

Qilu Pharmaceutical in Hematologic Neoplasms: 2 programs

  1. QLS2309phase 1
  2. QLS2313phase 1

Their studies: Qilu Pharmaceutical’s studies of Hematologic Neoplasms in search

Hypertension2 of 3 · compare here

AstraZeneca in Hypertension: 2 programs

  1. baxdrostatphase 3
  2. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Hypertension in search

–

Qilu Pharmaceutical in Hypertension: 1 program

  1. QLS1410phase 2

Their studies: Qilu Pharmaceutical’s studies of Hypertension in search

Myasthenia Gravis2 of 3 · compare here

AstraZeneca in Myasthenia Gravis: 2 programs

  1. ravulizumabapproved, new study
  2. eculizumabapproved, new study

Their studies: AstraZeneca’s studies of Myasthenia Gravis in search

Amgen in Myasthenia Gravis: 1 program

  1. inebilizumabapproved, new study

Their studies: Amgen’s studies of Myasthenia Gravis in search

–
Nasal Polyps2 of 3 · compare here

AstraZeneca in Nasal Polyps: 2 programs

  1. tezepelumabapproved, new study
  2. benralizumabapproved, new study

Their studies: AstraZeneca’s studies of Nasal Polyps in search

–

Qilu Pharmaceutical in Nasal Polyps: 1 program

  1. tezepelumabphase 3

Their studies: Qilu Pharmaceutical’s studies of Nasal Polyps in search

Neuromyelitis Optica2 of 3 · compare here

AstraZeneca in Neuromyelitis Optica: 2 programs

  1. ravulizumabapproved, new study
  2. eculizumabapproved, new study

Their studies: AstraZeneca’s studies of Neuromyelitis Optica in search

Amgen in Neuromyelitis Optica: 1 program

  1. inebilizumabapproved, new study

Their studies: Amgen’s studies of Neuromyelitis Optica in search

–
Osteoporosis2 of 3 · compare here–

Amgen in Osteoporosis: 1 program

  1. romosozumabapproved, new study

Their studies: Amgen’s studies of Osteoporosis in search

Qilu Pharmaceutical in Osteoporosis: 2 programs

  1. QL1206phase 3
  2. QLG2128phase 3

Their studies: Qilu Pharmaceutical’s studies of Osteoporosis in search

Ovarian Neoplasms2 of 3 · compare here

AstraZeneca in Ovarian Neoplasms: 2 programs

  1. saruparibphase 3
  2. torvutatug samrotecanphase 3

Their studies: AstraZeneca’s studies of Ovarian Neoplasms in search

–

Qilu Pharmaceutical in Ovarian Neoplasms: 1 program

  1. Platinum Compoundsphase 2

Their studies: Qilu Pharmaceutical’s studies of Ovarian Neoplasms in search

Sepsis2 of 3 · compare here

AstraZeneca in Sepsis: 2 programs

  1. Berzanoflastphase 2
  2. AZD7760phase 2

Their studies: AstraZeneca’s studies of Sepsis in search

–

Qilu Pharmaceutical in Sepsis: 1 program

  1. pralurbactamphase 3

Their studies: Qilu Pharmaceutical’s studies of Sepsis in search

Amyloid Neuropathies, Familial2 of 3 · compare here

AstraZeneca in Amyloid Neuropathies, Familial: 1 program

  1. acoramidisapproved, new study

Their studies: AstraZeneca’s studies of Amyloid Neuropathies, Familial in search

–

Qilu Pharmaceutical in Amyloid Neuropathies, Familial: 1 program

  1. Tafamidis Meglumine Soft Capsulesapproved, new study

Their studies: Qilu Pharmaceutical’s studies of Amyloid Neuropathies, Familial in search

Anemia, Aplastic2 of 3 · compare here–

Amgen in Anemia, Aplastic: 1 program

  1. romiplostimapproved, new study

Their studies: Amgen’s studies of Anemia, Aplastic in search

Qilu Pharmaceutical in Anemia, Aplastic: 1 program

  1. romiplostimphase 3

Their studies: Qilu Pharmaceutical’s studies of Anemia, Aplastic in search

Biliary Tract Neoplasms2 of 3 · compare here

AstraZeneca in Biliary Tract Neoplasms: 1 program

  1. rilvegostomigphase 3

Their studies: AstraZeneca’s studies of Biliary Tract Neoplasms in search

–
Carcinoma, Ovarian Epithelial2 of 3 · compare here

AstraZeneca in Carcinoma, Ovarian Epithelial: 1 program

  1. torvutatug samrotecanphase 3

Their studies: AstraZeneca’s studies of Carcinoma, Ovarian Epithelial in search

–

Qilu Pharmaceutical in Carcinoma, Ovarian Epithelial: 1 program

  1. QLS5132phase 3

Their studies: Qilu Pharmaceutical’s studies of Carcinoma, Ovarian Epithelial in search

Coronary Artery Disease2 of 3 · compare here

AstraZeneca in Coronary Artery Disease: 1 program

  1. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Coronary Artery Disease in search

Amgen in Coronary Artery Disease: 1 program

  1. evolocumabapproved, new study

Their studies: Amgen’s studies of Coronary Artery Disease in search

–
COVID-192 of 3 · compare here

AstraZeneca in COVID-19: 1 program

  1. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of COVID-19 in search

Amgen in COVID-19: 1 program

  1. apremilastapproved, new study

Their studies: Amgen’s studies of COVID-19 in search

–
Esophageal Squamous Cell Carcinoma2 of 3 · compare here–

Amgen in Esophageal Squamous Cell Carcinoma: 1 program

  1. tambotatug pelitecanphase 1

Their studies: Amgen’s studies of Esophageal Squamous Cell Carcinoma in search

Qilu Pharmaceutical in Esophageal Squamous Cell Carcinoma: 1 program

  1. QLC5508phase 3

Their studies: Qilu Pharmaceutical’s studies of Esophageal Squamous Cell Carcinoma in search

Glioblastoma2 of 3 · compare here

AstraZeneca in Glioblastoma: 1 program

  1. AZD1390phase 1

Their studies: AstraZeneca’s studies of Glioblastoma in search

–

Qilu Pharmaceutical in Glioblastoma: 1 program

  1. selinexorphase 3

Their studies: Qilu Pharmaceutical’s studies of Glioblastoma in search

Glomerulonephritis, IGA2 of 3 · compare here

AstraZeneca in Glomerulonephritis, IGA: 1 program

  1. Budesonideapproved, new study

Their studies: AstraZeneca’s studies of Glomerulonephritis, IGA in search

–

Qilu Pharmaceutical in Glomerulonephritis, IGA: 1 program

  1. QLS7305phase 2

Their studies: Qilu Pharmaceutical’s studies of Glomerulonephritis, IGA in search

Head and Neck Neoplasms2 of 3 · compare here

AstraZeneca in Head and Neck Neoplasms: 1 program

  1. monalizumabphase 3

Their studies: AstraZeneca’s studies of Head and Neck Neoplasms in search

–

Qilu Pharmaceutical in Head and Neck Neoplasms: 1 program

  1. Platinum Compoundsphase 2

Their studies: Qilu Pharmaceutical’s studies of Head and Neck Neoplasms in search

Hyperaldosteronism2 of 3 · compare here

AstraZeneca in Hyperaldosteronism: 1 program

  1. baxdrostatphase 3

Their studies: AstraZeneca’s studies of Hyperaldosteronism in search

–

Qilu Pharmaceutical in Hyperaldosteronism: 1 program

  1. QLS1410phase 2

Their studies: Qilu Pharmaceutical’s studies of Hyperaldosteronism in search

Liver Diseases2 of 3 · compare here

AstraZeneca in Liver Diseases: 1 program

  1. AZD2389phase 2

Their studies: AstraZeneca’s studies of Liver Diseases in search

Amgen in Liver Diseases: 1 program

  1. maridebart cafraglutidephase 3

Their studies: Amgen’s studies of Liver Diseases in search

–
Macular Degeneration2 of 3 · compare here–

Amgen in Macular Degeneration: 1 program

  1. afliberceptphase 3

Their studies: Amgen’s studies of Macular Degeneration in search

Qilu Pharmaceutical in Macular Degeneration: 1 program

  1. QL1207Hphase 3

Their studies: Qilu Pharmaceutical’s studies of Macular Degeneration in search

Multiple Sclerosis2 of 3 · compare here–

Qilu Pharmaceutical in Multiple Sclerosis: 1 program

  1. Dimethyl Fumarate Enteric-coated Capsulesapproved, new study

Their studies: Qilu Pharmaceutical’s studies of Multiple Sclerosis in search

Myelodysplastic Syndromes2 of 3 · compare here–

Amgen in Myelodysplastic Syndromes: 1 program

  1. romiplostimapproved, new study

Their studies: Amgen’s studies of Myelodysplastic Syndromes in search

Qilu Pharmaceutical in Myelodysplastic Syndromes: 1 program

  1. romiplostimphase 3

Their studies: Qilu Pharmaceutical’s studies of Myelodysplastic Syndromes in search

Osteoporosis, Postmenopausal2 of 3 · compare here–

Amgen in Osteoporosis, Postmenopausal: 1 program

  1. romosozumabapproved, new study

Their studies: Amgen’s studies of Osteoporosis, Postmenopausal in search

Qilu Pharmaceutical in Osteoporosis, Postmenopausal: 1 program

  1. QL1206phase 3

Their studies: Qilu Pharmaceutical’s studies of Osteoporosis, Postmenopausal in search

Precursor Cell Lymphoblastic Leukemia-Lymphoma2 of 3 · compare here

AstraZeneca in Precursor Cell Lymphoblastic Leukemia-Lymphoma: 1 program

  1. Menin Inhibitor AZD3632phase 2

Their studies: AstraZeneca’s studies of Precursor Cell Lymphoblastic Leukemia-Lymphoma in search

Amgen in Precursor Cell Lymphoblastic Leukemia-Lymphoma: 1 program

  1. blinatumomabapproved, new study

Their studies: Amgen’s studies of Precursor Cell Lymphoblastic Leukemia-Lymphoma in search

–
Psoriasis2 of 3 · compare here–

Amgen in Psoriasis: 1 program

  1. apremilastapproved, new study

Their studies: Amgen’s studies of Psoriasis in search

Qilu Pharmaceutical in Psoriasis: 1 program

  1. QL2106phase 3

Their studies: Qilu Pharmaceutical’s studies of Psoriasis in search

Purpura, Thrombocytopenic2 of 3 · compare here–

Amgen in Purpura, Thrombocytopenic: 1 program

  1. romiplostimapproved, new study

Their studies: Amgen’s studies of Purpura, Thrombocytopenic in search

Qilu Pharmaceutical in Purpura, Thrombocytopenic: 1 program

  1. romiplostimphase 3

Their studies: Qilu Pharmaceutical’s studies of Purpura, Thrombocytopenic in search

Rhinosinusitis2 of 3 · compare here

AstraZeneca in Rhinosinusitis: 1 program

  1. tezepelumabapproved, new study

Their studies: AstraZeneca’s studies of Rhinosinusitis in search

–

Qilu Pharmaceutical in Rhinosinusitis: 1 program

  1. tezepelumabphase 3

Their studies: Qilu Pharmaceutical’s studies of Rhinosinusitis in search

Uterine Cervical Neoplasms2 of 3 · compare here

AstraZeneca in Uterine Cervical Neoplasms: 1 program

  1. volrustomigphase 3

Their studies: AstraZeneca’s studies of Uterine Cervical Neoplasms in search

–

Qilu Pharmaceutical in Uterine Cervical Neoplasms: 1 program

  1. Iparomlimab/Tuvonralimabphase 3

Their studies: Qilu Pharmaceutical’s studies of Uterine Cervical Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetAstraZenecaAmgenQilu Pharmaceutical
CD3Esurovatamig, Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492, Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863, Anti-GPC3 T Cell-engaging Antibody AZD9793, Anti-STEAP2/Anti-CD3/Anti-CD8 Trispecific Antibody AZD6621blinatumomabrule, tarlatamabrule, xaluritamigruleAnti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905rule, QLS32015rule, QLS4131rule
KRASPan-KRAS Inhibitor JAB-23E73, AZD0240sotorasibrule, Pan-KRAS Inhibitor AMG 410ruleKRAS G12D Inhibitor QLC1101rule
CD19Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F, surovatamig, CT204V-CD19 × CD20ruleblinatumomabrule, inebilizumabrule–
CD8AAnti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492, Anti-GPC3 T Cell-engaging Antibody AZD9793, Anti-STEAP2/Anti-CD3/Anti-CD8 Trispecific Antibody AZD6621, CD8-guided IL-2 Fusion Protein AZD6750etakafusp alfarule–
CLDN18sonesitatug vedotin, Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863, Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360rule–Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905rule
CTLA4volrustomig, tremelimumabrule–Iparomlimab/Tuvonralimabrule
GPRC5Dvemzatatug vedotin–QLS32015rule, QLS4131rule
PCSK9–evolocumabruleQLC7401rule, RBD7022rule
PDCD1rilvegostomig, volrustomig–Iparomlimab/Tuvonralimabrule
CD276–tambotatug pelitecanAnti-B7-H3 Antibody-drug Conjugate MHB088Crule
ERBB2trastuzumab deruxtecanrule–Anti-HER2 Monoclonal Antibody QL1209rule
MPL–romiplostimruleromiplostimrule
TACSTD2datopotamab deruxtecanrule–Anti-TROP2 Antibody-drug Conjugate ESG401rule
TSLPtezepelumabrule–tezepelumabrule
A target, or a pathogen for a vaccine, known for: AstraZeneca 68 of 119 · Amgen 17 of 24 · Qilu Pharmaceutical 18 of 72 programs (63 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5).